Filana Therapeutics Inc (FLNA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.58-2.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · FLNA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
FLNA — litigation filed
Dated 2026-10-20
Other Events. On October 16, 2026, the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”) vacated the order of the U.S. District Court for the Western District of Texas (the “Texas District Court”) granting class certification in the securities class action pending against Filana Therapeutics, Inc. (the “Company”) and certain named officers and employees (together with the Company, the “Defendants”). Following the Company’s successful appeal, further proceedings regard…
Why it matters: The trial needs 13 U.S. sites and 40 patients. Site openings and enrollment updates will show whether the study can proceed as planned.
Watch forFilana says sites are open, and enrollment is nearing the 40-person target.
Also watch forFilana reports site delays, slow enrollment, or a change that lowers the 40-person target.
Why it matters: Nasdaq said Filana's share price was below $1 for 30 straight business days. Losing the listing could add pressure while the company funds its trial.
Worry ifFilana fails to regain a $1 closing bid for at least 10 straight business days before its Nasdaq compliance period ends.
Less concerning ifFilana reports that it met Nasdaq's $1 bid-price rule again.
Why it matters: Starting screening on time would show the trial is moving from planning to patient testing. A delay would push back the first human data.
Watch forFilana begins screening patients for the 40-person Phase 2a trial by March 31, 2027.
Also watch forFilana reports that screening has not begun by March 31, 2027, or pushes the start date later.
Why it matters: This trial will test simufilam in people with TSC-related epilepsy for the first time. Seizure and safety results can guide later studies.
Watch forStudy results show fewer or milder seizures. Safety findings support more testing.
Also watch forStudy results show no change in seizure measures, or safety findings that block more testing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$315 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $796 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,643 loss on $10,000 · 76.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The appeals court removed class status, but the case is not over. A new ruling could affect legal costs and the cash set aside for the case.
Watch forThe Fifth Circuit or district court ends the case or narrows the claims against Filana.
Also watch forThe case moves forward with class status restored or with new claims that raise Filana's legal exposure.